@article{66bf5fb9a44a481badd41d782dd645e4,
title = "Year-to-year changes in lung function in individuals with cystic fibrosis",
abstract = "Background: We examined the year-to-year change in FEV1 for individuals and the overall cystic fibrosis population to better understand how individual trends may differ from population trends. Methods: We calculated individual yearly changes using the largest annual FEV1 percent predicted (FEV1\%) measurement in 20,644 patients (6-45years old) included in the Epidemiologic Study of Cystic Fibrosis. We calculated yearly population changes using age-specific medians. Results: FEV1\% predicted decreased 1-3 points per year for individuals, with maximal decreases in 14-15year olds. Population changes agreed with individual changes up to age 15; however after age 30, yearly population change approximated zero while individual FEV1\% predicted decreases were 1-2 points per year. Conclusions: Adolescents have the greatest FEV1\% predicted decreases; however, loss of FEV1 is a persistent risk in 6-45year old CF patients. Recognizing individual year-to-year changes may improve patient-specific care and may suggest new methods for measuring program quality.",
keywords = "Annual trends, Cystic fibrosis, Pulmonary function",
author = "Liou, \{Theodore G.\} and Elkin, \{Eric P.\} and Pasta, \{David J.\} and Jacobs, \{Joan R.\} and Konstan, \{Michael W.\} and Morgan, \{Wayne J.\} and Wagener, \{Jeffrey S.\}",
note = "Funding Information: Theodore Liou, Michael Konstan, Wayne Morgan, and Jeffrey Wagener have received honoraria to attend meetings as members of the North American Scientific Advisory Group for the Epidemiologic Study of Cystic Fibrosis (ESCF). Theodore Liou has received funding from the NIH/NHLBI, the CF Foundation and the Ben B. and Ira M. Margolis Family Foundation of Utah for work related to CF. He is a member of the CF Foundation Patient Registry Data Use Committee and is a steering committee consultant on the REVEAL registry project on PAH sponsored by Actelion. As the principle investigator for the Therapeutic Development Network Center at the University of Utah, Dr. Liou has received funding to participate in trials of novel treatments for CF from Altus, Axcan-Scandipharm, Bayer, Boehringer, Genentech, Gilead, Inspire, Kalobios, MPEX, Novartis and Vertex. Dr. Liou has consulted for the Gehrson Lehman Group. Eric Elkin and David Pasta are employees of ICON Clinical Research, Inc., which was paid by Genentech to provide biostatistical and analytic services. Joan Jacobs is an employee of Genentech, Inc. Michael Konstan has received payment from Genentech, Inc., for serving as Co-Chair of the North American Scientific Advisory Group and as a consultant. Wayne Morgan has received payment from the Cystic Fibrosis Foundation for serving as Chair of the Cystic Fibrosis Data Safety Monitoring Board and from Genentech, Inc., for serving as Chair of the North American Scientific Advisory Group, and is the recipient of research grant support from Novartis for a study being conducted by the National Institute of Allergy and Infectious Diseases (NIAID) Inner City Asthma Consortium. Jeffrey Wagener was employed by Genentech until 2007, has done consultant work for Genentech and Gilead, is on advisory boards for Genentech and Gilead, and has received speaking honoraria from Genentech, Gilead, Roche, and Novartis during the last 3 years. ",
year = "2010",
month = jul,
doi = "10.1016/j.jcf.2010.04.002",
language = "English (US)",
volume = "9",
pages = "250--256",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier B.V.",
number = "4",
}